Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172145
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanjosé Llongueras, Silvia de-
dc.contributor.authorSerrano, Beatriz-
dc.contributor.authorTous, Sara-
dc.contributor.authorAlejo, Maria-
dc.contributor.authorLloveras Rubio, Betlem-
dc.contributor.authorQuirós, Beatriz-
dc.contributor.authorClavero, Omar-
dc.contributor.authorVidal-Bel, August-
dc.contributor.authorFerrándiz Pulido, Carla-
dc.contributor.authorPavón Ribas, Miquel Àngel-
dc.contributor.authorHolzinger, Dana-
dc.contributor.authorHalec, Gordana-
dc.contributor.authorTommasino, Massimo-
dc.contributor.authorQuint, Wim-
dc.contributor.authorPawlita, Michael-
dc.contributor.authorMuñoz, Nubia-
dc.contributor.authorBosch José, Francesc Xavier, 1947--
dc.contributor.authorAlemany i Vilches, Laia-
dc.contributor.authorRIS HPV TT, VVAP and Head and Neck study groups-
dc.date.accessioned2020-11-18T09:20:19Z-
dc.date.available2020-11-18T09:20:19Z-
dc.date.issued2018-11-01-
dc.identifier.issn2515-5091-
dc.identifier.urihttp://hdl.handle.net/2445/172145-
dc.description.abstractBackground: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherOxford University Press-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1093/jncics/pky045-
dc.relation.ispartofJNCI Cancer Spectrum, 2018, vol. 2, num. 4, p. pky045-
dc.relation.urihttps://doi.org/10.1093/jncics/pky045-
dc.rightscc by-nc (c) Sanjosé Llongueras et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationPapil·lomavirus-
dc.subject.classificationCàncer de coll uterí-
dc.subject.otherPapillomaviruses-
dc.subject.otherCervix cancer-
dc.titleBurden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec683951-
dc.date.updated2020-11-18T09:20:19Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/282562/EU//HPV-AHEAD-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31360870-
Appears in Collections:Publicacions de projectes de recerca finançats per la UE
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
683951.pdf2.97 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons